Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma

Table 1 Basic patient information

Characteristics	Number	Proportion (%)
Gender
Male	45	0.849
Female	8	0.151
Age (yr)
< 50	22	0.415
≥ 50	31	0.585
HBsAg
Positive	45	0.849
Negative	8	0.151
Liver cirrhosis
Yes	48	0.901
No	5	0.099
ECOG grade
0	26	0.491
1	27	0.509
Child-Pugh class
A	42	0.792
B	11	0.208
BCLC stage
B	27	0.509
C	26	0.491
Maximum tumor diameter (cm)
< 5	9	0.169
5-10	18	0.340
> 10	26	0.491
Tumor capsule
Complete	28	0.528
Incomplete	25	0.472
Alpha-fetoprotein (ng/mL)
< 400 ng/mL	23	0.434
≥ 400 ng/mL	30	0.566
Number of tumors
≤ 3	30	0.566
> 3	23	0.434
Vascular invasion
Vp2	5	0.099
Vp3	5	0.099
Vp4	11	0.208
Vv2	6	0.113
Vv3	0	0.000
Extrahepatic metastases
Yes	12	0.226
No	41	0.774
Lymph node metastases
Yes	6	0.113
No	47	0.887

HBsAg: Hepatitis B surface antigen; ECOG: Eastern Cooperative Oncology Group; PVTT: Portal vein tumor thrombus; BCLC: Barcelona Clinic Liver Cancer; Vp2: PVTT in the second-order branches of the portal vein; Vp3: PVTT in the first-order branch of the portal vein; Vp4: PVTT in the main trunk and/or a contralateral portal vein; Vv2: Hepatic vein trunk tumor thrombus.

Table 2 Tumor treatment response assessment, n (%)

Variables	CR	PR	SD	PD	ORR	DCR
mRECIST	13 (24.5)	19 (35.9)	21 (39.6)	0 (0)	32 (60.4)	53 (100.0)
RECIST V1.1	2 (3.8)	23 (43.4)	28 (52.8)	0 (0)	25 (47.2)	53 (100.0)

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate; mRECIST: Modified Response Evaluation Criteria in Solid Tumors.

Table 3 Patient treatment-related adverse events, n (%)

AEs	Any grade	Grade 1	Grade 2	Grade 3
Leukopenia	21 (39.62)	11 (20.75)	10 (18.87)	0
Thrombocytopenia	12 (22.64)	12 (22.64)	0 (0.00)	0
Rash	7 (13.21)	3 (5.66)	4 (7.55)	0
Itchy skin	5 (9.43)	5 (9.43)	0 (0.00)	0
Hand-foot syndrome	17 (32.08)	10 (18.87)	7 (13.21)	0
Increased serum ALT and AST levels	25 (47.17)	23 (43.40)	2 (3.77)	0
Increased serum bilirubin	8 (15.09)	6 (11.32)	2 (3.77)	0
Diarrhea	5 (9.43)	3 (5.66)	2 (3.77)	0
Nausea, vomiting	24 (45.28)	13 (24.53)	11 (20.75)	0
Proteinuria	10 (18.87)	4 (7.55)	6 (11.32)	0
Hypothyroidism	16 (30.19)	0 (0.00)	16 (30.19)	0
Gastrointestinal bleeding	5 (9.43)	0 (0.00)	1 (1.88)	4 (7.55)
Stomachache	17 (32.08)	10 (18.87)	7 (13.21)	0
Hair loss	4 (7.55)	4 (7.55)	0 (0.00)	0
Weight loss	9 (16.98)	9 (16.98)	0 (0.00)	0
Decreased appetite	25 (47.17)	23 (43.40)	2 (3.77)	0
Fatigue	19 (35.85)	19 (35.85)	0 (0.00)	0
Hypertension	24 (45.28)	2 (3.77)	22 (41.51)	0